Concord Biotech Ltd (CONCORDBIO) is currently trading at 1,245.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Concord Biotech Limited is an R&D-driven biopharmaceutical manufacturer producing fermentation-based APIs and finished formulations across immunosuppressant, oncology, anti-infective, antifungal and related therapy areas. It operates four facilities in Gujarat, serves more than 70 countries and combines fermentation expertise, backward integration, formulation development and global regulatory capabilities. Q2FY27 revenue rose 25% year on year to ₹309.1 crore, while H1FY27 revenue increased 26% to ₹566.6 crore. API growth was the principal engine, with H1 revenue expanding 36% and reaching 83% of the mix, whereas formulations declined 8% during the half year despite quarterly growth and new product initiatives. Profit growth trailed revenue growth because higher input costs and an unfavorable product mix compressed Q2 EBITDA margin by 200 basis points and PAT margin by 300 basis points. Excluding the injectable facility and Stellon-related expenses, management reported a stronger Q2 EBITDA margin of 37.1%, indicating meaningful reported-margin drag from expansion investments. The launch of Inspira establishes a new dermatology division, while two ANDA approvals for Tofacitinib and MMF OS strengthen the company’s regulated-market pipeline. Completion of the USFDA inspection at the Valthera formulation facility with one minor procedural observation also supports continuity of international supplies and reinforces Concord’s compliance credentials. Concord Biotech Limited remains financially conservative, reporting no borrowings and ₹168.2 crore of operating cash flow in H1FY27. However, cash and equivalents declined to approximately ₹7.5 crore as investing and financing outflows exceeded operating inflows, while inventories increased materially, making working-capital discipline important alongside growth execution.

Over the past 52 weeks, Concord Biotech Ltd has traded between a low of ₹987.05 and a high of ₹1,614.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Concord Biotech Ltd has a market capitalization of approximately 12,866.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Concord Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 46.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12,866.75 Cr, Concord Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Concord Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 46.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Concord Biotech reported consolidated revenue from operations of ₹309.07 crore for Q2 FY27, converted from ₹30,907.02 lakh disclosed in its BSE filing.

It disclosed the voting results along with the scrutinizer’s report for the business items transacted at its 41st AGM, pursuant to SEBI LODR Regulation 44(3) and Companies Act Section 108.

The board is scheduled to meet on Wednesday, September 23, 2026, to consider the proposal for bonus equity shares.

The stock rose after Concord Biotech announced USFDA final approval for its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths.